Documents
Resources
Learning Center
Upload
Plans & pricing Sign in
Sign Out

United Therapeutics Corporation (UTHR) - Financial and Strategic Analysis Review

VIEWS: 38 PAGES: 37

United Therapeutics Corporation (UTC) is a biotechnology company engaged in the development and commercialization of innovative therapeutic products for the cardiovascular, cancer and other infectious disease markets. The company operates in two business segments namely, pharmaceutical and telemedicine. Its products are used in the treatment of pulmonary arterial hypertension, cardiac arrhythmias and ischemic heart disease, neuroblastoma, metastatic brain cancer, idiopathic pulmonary fibrosis, hepatitis C and other infectious diseases. The company principally operates in the US and markets its products across Europe, South America and Israel. It is headquartered in Maryland, United States. United Therapeutics Corporation Key Recent Developments May 25, 2010 United Therapeutics Launches Living PAH Program Apr 29, 2010 United Therapeutics Reports Net Income Of $18.9 Million In Q1 2010 Apr 29, 2010 United Therapeutics Reports Net Income Of $18.9 Million For Q1 2010 Feb 19, 2010 United Therapeutics Withdraws Tyvaso Marketing Authorization Application Feb 16, 2010 United Therapeutics Reports Net Income Of $19.5 Million In 2009 This comprehensive SWOT profile of United Therapeutics Corporation provides you an in-depth strategic analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better. The profile contains critical company information including, - Business description – A detailed description of the company’s operations and business divisions. - Corporate strategy – Analyst’s summarization of the company’s business strategy. - SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.

More Info
									             United Therapeutics Corporation (UTHR) - Financial and Strategic
                                    Analysis Review

       Reference Code: GDME1845FSA                                                                                      Publication Date: AUG 2010

       1040 Spring Street                   Phone             +1 301 6089292                          Revenue            369.9 (million USD)
       Silver Spring, MD                    Fax               +1 301 6089291                          Net Profit         19.46 (million USD)
       20910                                Website           www.unither.com                         Employees          410
       United States                        Exchange          UTHR [NASDAQ]                           Industry           Medical Equipment

      Company Overview
       United Therapeutics Corporation (UTC) is a biotechnology company engaged in the development and commercialization of
       innovative therapeutic products for the cardiovascular, cancer and other infectious disease markets. The company operates in
       two business segments namely, pharmaceutical and telemedicine. Its products are used in the treatment of pulmonary arterial
       hypertension, cardiac arrhythmias and ischemic heart disease, neuroblastoma, metastatic brain cancer, idiopathic pulmonary
       fibrosis, hepatitis C and other infectious diseases. The company principally operates in the US and markets its products across
       Europe, South America and Israel. It is headquartered in Maryland, United States.

      Key Executives                                                                 SWOT Analysis
                     Name                                   Title                    United Therapeutics Corporation, SWOT Analysis
      Martine Rothblatt, Ph.D.              Chairman                                 Strengths                  Weaknesses

      Roger Jeffs, Ph.D.                    Chief Operating Officer
                                                                                     Expanding Operating Margin         Limited Liquidity Position
      Christopher Causey                    Director
      R. Paul Gray                          Director                                 Strong Growth Prospects            Confined Customer Base
      Ray Kurzweil                          Director
      Source: Annual Report, Company Website, Primary and Secondary Research
      GlobalData
                                                                                     Opportunities                      Threats
      Share Data
                                                                                     Biotech Focus                      Pricing Pressures
       United Therapeutics Corporation
       Share Price (USD) as on 25-Aug-2010                                47.30      Rising Healthcare                  Healthcare Reform Bill
                                                                            0.35     Expenditure in the US
       EPS (USD)
       Market Cap (million USD)                                           2,672

       Enterprise Value (million USD)                                     2,646
                                                                                     Source: Annual Report, Company Website, Primary and Secondary
       Shares Outstanding (million)                                             56   Research
       Source: Annual Report, Company Website, Primary and Secondary Research        GlobalData
       GlobalData

      Financial Performance                                                          Recent Developments
                                                                                     May 25, 2010        United Therapeutics Launches Living PAH
                                                                                                         Program
                                                                                     Apr 29, 2010        United 
								
To top